Interpace Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.09 (-0.88 %)
(As of 06/10/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume25,335 shs
Average Volume13,237 shs
Market Capitalization$41.76 million
P/E RatioN/A
Dividend YieldN/A

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Interpace Biosciences logo

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.17 out of 5 stars

Medical Sector

995th out of 2,096 stocks

Surgical & Medical Instruments Industry

96th out of 174 stocks

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Interpace Biosciences (NASDAQ:IDXG) Frequently Asked Questions

Is Interpace Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Interpace Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Interpace Biosciences stock.
View analyst ratings for Interpace Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Interpace Biosciences?

Wall Street analysts have given Interpace Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Interpace Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Interpace Biosciences' next earnings date?

Interpace Biosciences is scheduled to release its next quarterly earnings announcement on Monday, October 18th 2021.
View our earnings forecast for Interpace Biosciences

How were Interpace Biosciences' earnings last quarter?

Interpace Biosciences, Inc. (NASDAQ:IDXG) issued its quarterly earnings data on Tuesday, May, 11th. The business services provider reported ($1.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.43) by $0.41. The business services provider had revenue of $9.83 million for the quarter, compared to analysts' expectations of $9 million.
View Interpace Biosciences' earnings history

What guidance has Interpace Biosciences issued on next quarter's earnings?

Interpace Biosciences updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $42 million-$44 million, compared to the consensus revenue estimate of $39.60 million.

What price target have analysts set for IDXG?

2 brokers have issued twelve-month price targets for Interpace Biosciences' shares. Their forecasts range from $7.00 to $11.00. On average, they anticipate Interpace Biosciences' share price to reach $9.00 in the next year. This suggests that the stock has a possible downside of 11.4%.
View analysts' price targets for Interpace Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Interpace Biosciences' key executives?

Interpace Biosciences' management team includes the following people:
  • Dr. Thomas W. Burnell Ph.D., Pres, CEO & Director (Age 58, Pay $425k)
  • Mr. Thomas John Freeburg Ph.D., Chief Accounting Officer, CFO, Treasurer & Sec. (Age 52)
  • Dr. Sydney D. Finkelstein, Chief Scientific Officer
  • Dr. Alidad Mireskandari M.B.A., Ph.D., Chief Devel. Officer
  • Mr. Patrick Kane, VP & Corp. Controller

Who are some of Interpace Biosciences' key competitors?

What other stocks do shareholders of Interpace Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

What is Interpace Biosciences' stock symbol?

Interpace Biosciences trades on the NASDAQ under the ticker symbol "IDXG."

Who are Interpace Biosciences' major shareholders?

Interpace Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include HRT Financial LP (0.27%).
View institutional ownership trends for Interpace Biosciences

Which major investors are buying Interpace Biosciences stock?

IDXG stock was purchased by a variety of institutional investors in the last quarter, including HRT Financial LP.
View insider buying and selling activity for Interpace Biosciences
or or view top insider-buying stocks.

What is Interpace Biosciences' stock price today?

One share of IDXG stock can currently be purchased for approximately $10.16.

How much money does Interpace Biosciences make?

Interpace Biosciences has a market capitalization of $41.76 million and generates $32.40 million in revenue each year. The business services provider earns $-26,450,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis.

How many employees does Interpace Biosciences have?

Interpace Biosciences employs 152 workers across the globe.

What is Interpace Biosciences' official website?

The official website for Interpace Biosciences is

Where are Interpace Biosciences' headquarters?

Interpace Biosciences is headquartered at MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054.

How can I contact Interpace Biosciences?

Interpace Biosciences' mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.